We are live on ! Find out more
ALNY icon

Alnylam Pharmaceuticals
ALNY

282 hedge funds and large institutions have $11.7B invested in Alnylam Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 76 funds opening new positions, 102 increasing their positions, 65 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

171% more first-time investments, than exits

New positions opened: 76 | Existing positions closed: 28

57% more repeat investments, than reductions

Existing positions increased: 102 | Existing positions reduced: 65

20% more funds holding

Funds holding: 235 → 282 (+47)

17% more funds holding in top 10

Funds holding in top 10: 12 → 14 (+2)

14% more call options, than puts

Call options by funds: $165M | Put options by funds: $144M

14% more capital invested

Capital invested by funds: $10.3B → $11.7B (+$1.43B)

1.69% less ownership

Funds ownership: 95.44% → 93.75% (-1.7%)

Holders
282
Holders Change
+47
Holders Change %
+20%
% of All Funds
6.4%
Holding in Top 10
14
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+16.67%
% of All Funds
0.32%
New
76
Increased
102
Reduced
65
Closed
28
Calls
$165M
Puts
$144M
Net Calls
+$20.6M
Net Calls Change
-$48.6M

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$461M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$140M
3
BlackRock
BlackRock
New York
+$126M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$96.9M
5
PC
Polar Capital
United Kingdom
+$64.9M

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$266M
2
Dodge & Cox
Dodge & Cox
California
-$114M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$89.2M
4
Goldman Sachs
Goldman Sachs
New York
-$76.2M
5
PA
Perceptive Advisors
New York
-$57.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
PMFA
276
Plante Moran Financial Advisors
Michigan
$2K -$251 -2 -14%
AssetMark Inc
277
AssetMark Inc
California
$2K +$1.38K +11 +367%
MOS
278
MGO One Seven
Ohio
$2K +$1.63K +13 New
TWA
279
TCI Wealth Advisors
Arizona
$1K – – –
WA
280
Winfield Associates
Ohio
$1K – – –
PP
281
PDT Partners
New York
– -$27.9M -237,626 Closed
PI
282
Putnam Investments
Massachusetts
– -$15.8M -134,572 Closed
WG
283
Winton Group
United Kingdom
– -$10.6M -90,504 Closed
BC
284
Broadfin Capital
New York
– -$8.72M -74,208 Closed
Arrowstreet Capital
285
Arrowstreet Capital
Massachusetts
– -$6.05M -51,485 Closed
Millennium Management
286
Millennium Management
New York
– -$6.01M -51,125 Closed
LP
287
LMR Partners
United Kingdom
– -$5.94M -50,588 Closed
Axa
288
Axa
France
– -$4.74M -40,316 Closed
GTC
289
Ghost Tree Capital
New York
– -$4.11M -35,000 Closed
SEC
290
Seven Eight Capital
New York
– -$2.54M -21,584 Closed
SCM
291
Sio Capital Management
New York
– -$2.38M -20,225 Closed
HCM
292
Highbridge Capital Management
New York
– -$1.6M -13,656 Closed
SB
293
Suntrust Banks
Georgia
– -$1.08M -9,198 Closed
NFA
294
Nationwide Fund Advisors
Ohio
– -$936K -7,964 Closed
AGM
295
Alpine Global Management
New York
– -$871K -7,410 Closed
American Century Companies
296
American Century Companies
Missouri
– -$730K -6,217 Closed
NB
297
NBT Bank
New York
– -$717K -6,100 Closed
CI
298
Cowen Inc
New York
– -$670K -5,700 Closed
ARTA
299
A.R.T. Advisors
New York
– -$657K -5,600 Closed
GAM
300
Gotham Asset Management
New York
– -$294K -2,499 Closed
9 10 11
12
13

ALNY Hedge Fund Activity: Q4 2017 in Review

282 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q4 2017, worth a combined $11.7B — up 14% from $10.3B a quarter earlier.

Buyers outnumbered sellers: 76 funds opened new ALNY positions and 28 closed out — a net gain of 48 holders — while 102 added to existing stakes and 65 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $461M. The largest seller was Wellington Management Group, cutting an estimated $266M.

  • 282 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q4 2017, up from 235 in Q3 2017.
  • Funds reported $11.7B of Alnylam Pharmaceuticals stock for Q4 2017, up 14% quarter-over-quarter.
  • 76 funds opened new Alnylam Pharmaceuticals positions in Q4 2017 and 28 closed out, a net change of +48 holders.
  • The largest Alnylam Pharmaceuticals buyer in Q4 2017 was T. Rowe Price Associates, an estimated $461M added.
  • The largest Alnylam Pharmaceuticals seller in Q4 2017 was Wellington Management Group, an estimated $266M sold.

Based on aggregated 13F filings for Q4 2017.